

# Anthony D Ho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3188173/publications.pdf>

Version: 2024-02-01

185  
papers

5,950  
citations

136950

32  
h-index

76900

74  
g-index

208  
all docs

208  
docs citations

208  
times ranked

9660  
citing authors

#	ARTICLE	IF	CITATIONS
1	Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process. PLoS ONE, 2008, 3, e2213.	2.5	939
2	Human haematopoietic stem cell lineage commitment is a continuous process. Nature Cell Biology, 2017, 19, 271-281.	10.3	709
3	Aging and Replicative Senescence Have Related Effects on Human Stem and Progenitor Cells. PLoS ONE, 2009, 4, e5846.	2.5	405
4	DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell, 2010, 9, 54-63.	6.7	378
5	A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood, 2014, 124, 2325-2332.	1.4	366
6	Mesenchymal Stem Cell Preparations—Comparing Apples and Oranges. Stem Cell Reviews and Reports, 2007, 3, 239-248.	5.6	242
7	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	1.4	193
8	Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. Journal of Clinical Oncology, 2015, 33, 1371-1378.	1.6	185
9	Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy, 2015, 17, 128-139.	0.7	118
10	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood, 2016, 127, 2847-2855.	1.4	100
11	Polymorphisms of the tumor necrosis factor- $\beta$ gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 2002, 100, 2263-2265.	1.4	91
12	Aging of hematopoietic stem cells is regulated by the stem cell niche. Experimental Gerontology, 2008, 43, 974-980.	2.8	89
13	Hematopoietic Progenitor Cells and Cellular Microenvironment: Behavioral and Molecular Changes upon Interaction. Stem Cells, 2005, 23, 1180-1191.	3.2	81
14	Cell Division Patterns in Acute Myeloid Leukemia Stem-like Cells Determine Clinical Course: A Model to Predict Patient Survival. Cancer Research, 2015, 75, 940-949.	0.9	79
15	Human Mesenchymal Stromal Cells Regulate Initial Self-Renewing Divisions of Hematopoietic Progenitor Cells by a $\beta$ 1-Integrin-Dependent Mechanism. Stem Cells, 2007, 25, 798-806.	3.2	75
16	Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Molecular Systems Biology, 2017, 13, 904.	7.2	72
17	Stem cells and ageing. EMBO Reports, 2005, 6, S35-8.	4.5	71
18	Cell-specific proteome analyses of human bone marrow reveal molecular features of age-dependent functional decline. Nature Communications, 2018, 9, 4004.	12.8	71

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. <i>Blood</i> , 2016, 128, 594-602.	1.4	67
20	N-Cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. <i>Stem Cell Research</i> , 2010, 4, 129-139.	0.7	66
21	Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. <i>British Journal of Haematology</i> , 2001, 115, 605-608.	2.5	62
22	Correlation Between IL-6 Receptor Expression and Growth Potential of Human CD34 <sup>+</sup> Hematopoietic Cells from Different Tissues. <i>Stem Cells</i> , 1999, 17, 265-272.	3.2	61
23	Kinetics and symmetry of divisions of hematopoietic stem cells. <i>Experimental Hematology</i> , 2005, 33, 1-8.	0.4	59
24	The beauty of asymmetry: asymmetric divisions and self-renewal in the haematopoietic system. <i>Current Opinion in Hematology</i> , 2007, 14, 330-336.	2.5	55
25	Mitoxantrone/high-dose ara-c and recombinant human gm-csf in the treatment of refractory non-hodgkin's lymphoma a pilot study. <i>Cancer</i> , 1990, 66, 423-430.	4.1	46
26	The rarity of ALDH <sup>+</sup> cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. <i>International Journal of Cancer</i> , 2015, 137, 525-536.	5.1	46
27	Favorable therapeutic index of a p210 BCR-ABL -specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 433-438.	2.3	43
28	Frequent mechanical stress suppresses proliferation of mesenchymal stem cells from human bone marrow without loss of multipotency. <i>Scientific Reports</i> , 2016, 6, 24264.	3.3	39
29	Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. <i>Haematologica</i> , 2017, 102, 1424-1431.	3.5	39
30	Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. <i>British Journal of Haematology</i> , 1999, 105, 786-794.	2.5	37
31	Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection. <i>Journal of Clinical Apheresis</i> , 2017, 32, 27-34.	1.3	37
32	Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1567-1577.	3.5	37
33	Nek2 kinase displaces distal appendages from the mother centriole prior to mitosis. <i>Journal of Cell Biology</i> , 2020, 219, .	5.2	35
34	Feedback Signals in Myelodysplastic Syndromes: Increased Self-Renewal of the Malignant Clone Suppresses Normal Hematopoiesis. <i>PLoS Computational Biology</i> , 2014, 10, e1003599.	3.2	34
35	Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. <i>Cancer</i> , 1989, 64, 1388-1392.	4.1	32
36	The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2018, 97, 1241-1250.	1.8	31

#	ARTICLE	IF	CITATIONS
37	Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. <i>British Journal of Haematology</i> , 2015, 171, 710-719.	2.5	30
38	Microcavity arrays as an in vitro model system of the bone marrow niche for hematopoietic stem cells. <i>Cell and Tissue Research</i> , 2016, 364, 573-584.	2.9	30
39	Lenalidomide enhances myeloma-specific T-cell responses <i>in vivo</i> and <i>in vitro</i> . <i>Oncology</i> , 2016, 5, e1139662.	4.6	30
40	Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 1999, 106, 545-552.	2.5	28
41	Evaluation of GMP-compliant culture media for <i>in vitro</i> expansion of human bone marrow mesenchymal stromal cells. <i>Experimental Hematology</i> , 2016, 44, 508-518.	0.4	28
42	Microchimerism in bone marrow-derived CD34+ cells of patients after liver transplantation. <i>Blood</i> , 2000, 96, 763-767.	1.4	26
43	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. <i>Blood Advances</i> , 2020, 4, 6157-6168.	5.2	26
44	Identifying leukemia stem cells – Is it feasible and does it matter?. <i>Cancer Letters</i> , 2013, 338, 10-14.	7.2	25
45	Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. <i>Cancer Medicine</i> , 2016, 5, 1464-1472.	2.8	25
46	Hematopoietic stem cells: can old cells learn new tricks?. <i>Journal of Leukocyte Biology</i> , 2003, 73, 547-555.	3.3	24
47	The extracellular matrix proteins type I collagen, type III collagen, fibronectin, and laminin 421 stimulate migration of cancer cells. <i>FASEB Journal</i> , 2021, 35, e21692.	0.5	24
48	HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.. <i>Blood</i> , 2005, 106, 424-424.	1.4	24
49	Experience with a Therapeutic Platelet Transfusion Strategy in Acute Myeloid Leukemia: Preliminary Results of a Randomized Multicenter Study After Enrolment of 175 Patients.. <i>Blood</i> , 2009, 114, 20-20.	1.4	24
50	Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 684-690.	2.0	23
51	Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces. <i>Biomaterials</i> , 2014, 35, 1411-1419.	11.4	22
52	Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. <i>Oncotarget</i> , 2014, 5, 10237-10250.	1.8	22
53	High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. <i>BMC Cancer</i> , 2017, 17, 151.	2.6	21
54	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1575-1580.	2.0	20

#	ARTICLE	IF	CITATIONS
55	Etoposide in acute leukemia. Past experience and future perspectives. <i>Cancer</i> , 1991, 67, 281-284.	4.1	19
56	Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor. <i>Cytotherapy</i> , 2014, 16, 111-121.	0.7	19
57	Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance. <i>Biotechnology Journal</i> , 2012, 7, 779-788.	3.5	17
58	Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. <i>European Journal of Haematology</i> , 2016, 97, 78-82.	2.2	17
59	Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. <i>Transfusion</i> , 2017, 57, 2359-2365.	1.6	17
60	The Hematopoietic Supportive Potential of Human Mesenchymal Stromal Cells Is Associated with Expression of Cadherins.. <i>Blood</i> , 2006, 108, 1402-1402.	1.4	17
61	Infectious complications in chronic lymphoid malignancy. <i>Current Treatment Options in Oncology</i> , 2001, 2, 237-244.	3.0	15
62	Pentostatin for the Treatment of Indolent Lymphoproliferative Disorders. <i>Seminars in Hematology</i> , 2006, 43, S2-S10.	3.4	15
63	Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28 <sup>+</sup> T-cells. <i>Oncotarget</i> , 2017, 8, 98200-98214.	1.8	15
64	Retroviral Integration Sites Correlate with Expressed Genes in Hematopoietic Stem Cells. <i>Stem Cells</i> , 2005, 23, 1050-1058.	3.2	14
65	Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 1712-1721.	7.0	14
66	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 145-152.	1.5	13
67	The molecular signature of AML with increased ALDH activity suggests a stem cell origin. <i>Leukemia and Lymphoma</i> , 2018, 59, 2201-2210.	1.3	12
68	Glycogen accumulation, central carbon metabolism, and aging of hematopoietic stem and progenitor cells. <i>Scientific Reports</i> , 2020, 10, 11597.	3.3	12
69	Bone Marrow Harvesting of Allogeneic Donors in an Outpatient Setting: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 470-474.	2.0	10
70	Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.. <i>Blood</i> , 2009, 114, 717-717.	1.4	10
71	Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 99, 392-398.	2.2	8
72	New Class of Crosslinker-Free Nanofiber Biomaterials from Hydra Nematocyst Proteins. <i>Scientific Reports</i> , 2019, 9, 19116.	3.3	8

#	ARTICLE	IF	CITATIONS
73	Dynamic cellular phenotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1 $\alpha$ versus synthetic agents. <i>Scientific Reports</i> , 2018, 8, 1841.	3.3	7
74	Rituximab, Age and High Dose Therapy Followed By Autologous Stem Cell Transplantation Are Independent Prognostic Factors for Survival in the First Line Treatment of Primary CNS-Lymphoma. <i>Blood</i> , 2014, 124, 1727-1727.	1.4	7
75	Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1397-1402.	2.0	6
76	Glucose Metabolism and Aging of Hematopoietic Stem and Progenitor Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3028.	4.1	6
77	Pentostatin and purine analogs for indolent lymphoid malignancies. <i>Future Oncology</i> , 2006, 2, 169-183.	2.4	5
78	Clinical impact of $\text{KMT}2\text{C}$ and $\text{SPRY}4$ expression levels in intensively treated younger adult acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2017, 99, 544-552.	2.2	5
79	Simple Physical Model Unravels Influences of Chemokine on Shape Deformation and Migration of Human Hematopoietic Stem Cells. <i>Scientific Reports</i> , 2018, 8, 10630.	3.3	5
80	The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 30-37.	2.4	5
81	Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones. <i>International Journal of Cancer</i> , 2021, 148, 2825-2838.	5.1	5
82	Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi-Center Trial AML2003. <i>Blood</i> , 2008, 112, 978-978.	1.4	5
83	Molecular Composition of Intercellular Contacts in Human Mesenchymal Stem Cells. <i>Blood</i> , 2004, 104, 2332-2332.	1.4	5
84	Bone marrow-derived cells as carriers of recombinant immunomodulatory cytokine genes to lymphoid organs. <i>Cancer Gene Therapy</i> , 2000, 7, 1105-1112.	4.6	4
85	The FBMD-1 stroma cell line secretes a unique moiety which can increase retroviral transduction of lineage-committed and primitive human peripheral blood progenitor cells. <i>Cancer Gene Therapy</i> , 2001, 8, 440-449.	4.6	4
86	Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening. <i>Genome Medicine</i> , 2015, 7, 46.	8.2	4
87	Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia. <i>Blood</i> , 2005, 106, 1105-1105.	1.4	4
88	Pluripotent Stem Cells from Umbilical Cord Blood. <i>Blood</i> , 2006, 107, 73-89.		3
89	The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 2017, 96, 1501-1507.	1.8	3
90	Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 12-20.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Evolution of Peripheral Blood Stem Cell Transplantation. <i>Methods in Molecular Biology</i> , 2019, 2017, 1-10.	0.9	3
92	Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results. <i>Blood</i> , 2011, 118, 589-589.	1.4	3
93	Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study. <i>Blood</i> , 2012, 120, 1612-1612.	1.4	3
94	Low Vitamin D Levels Are Associated with Inferior Survival Following Azacitidine Treatment in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 1699-1699.	1.4	3
95	Endothelial Progenitor Cells for Cardiac Regeneration. , 2006, , 177-195.		2
96	Good Manufacturing Practices: Clinical-Scale Production of Mesenchymal Stem Cells. , 2006, , 91-105.		2
97	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001123.	1.2	2
98	How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).. <i>Blood</i> , 2004, 104, 4584-4584.	1.4	2
99	Sufficient Mobilization of Peripheral Blood Stem Cells by Single Dose Application of Pegylated G-CSF in Patients with Multiple Myeloma, Interim Analysis of a Phase II Study.. <i>Blood</i> , 2004, 104, 946-946.	1.4	2
100	A Phase IIIb Study of Rituximab Maintenance Therapy in Patients with Follicular Non-Hodgkinâ€™s Lymphoma Who Have Responded to Induction Therapy - MAXIMA-Protocol.. <i>Blood</i> , 2006, 108, 4706-4706.	1.4	2
101	The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study. <i>Blood</i> , 2008, 112, 839-839.	1.4	2
102	Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis. <i>Blood</i> , 2015, 126, 1790-1790.	1.4	2
103	N-Cadherin and Cadherin-11 Play Vital Roles in the Cell-Cell Contact between Hematopoietic Progenitor Cells and Mesenchymal Stromal Cells.. <i>Blood</i> , 2007, 110, 1406-1406.	1.4	2
104	Cellular Interaction Between Human Mesenchymal Stem Cells and Hematopoietic Stem Cells in 2D- and 3D-Culture-Systems.. <i>Blood</i> , 2009, 114, 1442-1442.	1.4	2
105	Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.. <i>Blood</i> , 2012, 120, 2911-2911.	1.4	2
106	Alteration of Hematopoietic Stem Cell Fates by Chromatin-Modifying Agents. , 2006, , 27-42.		1
107	Multimodality Treatment in Adult Patients with High-risk Soft-tissue Sarcomas. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 2-7.	0.1	1
108	Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1446-1454.	1.3	1

#	ARTICLE	IF	CITATIONS
109	Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity.. Blood, 2004, 104, 2094-2094.	1.4	1
110	Molecular Characterization of Unique Junctional Complexes as Communication Pathways among Mesenchymal Stem Cells.. Blood, 2005, 106, 1399-1399.	1.4	1
111	Favorable Influence of Pretransplant Rituximab but Not of High-Dose Ara-C in Upfront Autologous Stem Cell Transplantation (SCT) for Mantle Cell Lymphoma (MCL).. Blood, 2005, 106, 2089-2089.	1.4	1
112	Treatment of Imatinib-Sensitive and -Resistant Chronic Myelogenous Leukemia Cells with a Combination of Imatinib and Farnesyltransferase Inhibitors.. Blood, 2005, 106, 4881-4881.	1.4	1
113	Adhesion of Hematopoietic Progenitor Cells to Human Mesenchymal Stromal Cells as a Model for Interaction between Stem Cells and Their Niche.. Blood, 2006, 108, 1399-1399.	1.4	1
114	Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.. Blood, 2007, 110, 2500-2500.	1.4	1
115	Human Hematopoietic Stem Cells and Leukemic Cells Form Cadherin-Catenin Based Junctional Complexes with Mesenchymal Stromal Cells. Blood, 2008, 112, 1367-1367.	1.4	1
116	Centrosomal Clustering â€” a Novel Therapeutic Target for Multiple Myeloma.. Blood, 2009, 114, 300-300.	1.4	1
117	Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.. Blood, 2009, 114, 3401-3401.	1.4	1
118	Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV. Blood, 2011, 118, 782-782.	1.4	1
119	The Chromosomal Abnormalities Del(17p), t(4;14), and +1q21 Predict Progression From Smoldering to Symptomatic Multiple Myeloma. Blood, 2012, 120, 1806-1806.	1.4	1
120	Rituximab Maintenance Therapy After Autologous Stem Cell Transplantation Prolongs Progression Free Survival In Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 3050-3050.	1.4	1
121	ATG and Statins Reduce Incidence of Severe Chronic Gvhd By Distinct Mechanisms Involving CXCL9 and Kynurenine Catabolism. Blood, 2015, 126, 856-856.	1.4	1
122	No Influence of Previous Thalidomide Administration on Peripheral Blood Stem Cell Collection in Patients with Multiple Myeloma.. Blood, 2004, 104, 4902-4902.	1.4	1
123	Interaction of Stem Cells and Their Niche: Behavior and Gene Expression Profiles of CD34+/CD38âˆ’ Cells upon Co-Cultivation with AFT024.. Blood, 2004, 104, 1281-1281.	1.4	1
124	AMD3100 Inhibits Chemotaxis towards SDF-1 and CXCR4-Mediated Stroma-Contact in a Dose-Dependent Manner, Resulting in Increased Susceptibility to Imatinib.. Blood, 2006, 108, 4799-4799.	1.4	1
125	Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells.. Blood, 2007, 110, 2413-2413.	1.4	1
126	Proliferation and Activation Patterns of Naïve, Memory and Regulatory T Cells in Patients with Multiple Myeloma During Thalidomide, Interferon-Î± and Bortezomib Maintenance Therapy.. Blood, 2009, 114, 3880-3880.	1.4	1



#	ARTICLE	IF	CITATIONS
127	Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.. Blood, 2009, 114, 2823-2823.	1.4	1
128	Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV. Blood, 2011, 118, 781-781.	1.4	1
129	Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,. Blood, 2011, 118, 3700-3700.	1.4	1
130	BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. Blood, 2012, 120, 4040-4040.	1.4	1
131	Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity. Blood, 2012, 120, 4966-4966.	1.4	1
132	Proteomics Analysis of Cellular Network in Human Bone Marrow Reveals Lineage Skewing Towards Megakaryocytes and Decrease in Lymphoid Development upon Aging. Blood, 2016, 128, 2658-2658.	1.4	1
133	Characteristic Amino Acid and Energy Metabolism in AML Stem Cells As Revealed By Quantitative Multiplex Proteomics. Blood, 2018, 132, 2780-2780.	1.4	1
134	Elevated Central Carbon Metabolism - a Hallmark for Senescent Cells in Aging Human Hematopoietic Stem Cell Compartment. Blood, 2021, 138, 1088-1088.	1.4	1
135	The Ribomethylome Landscape of Hematopoietic System. Blood, 2020, 136, 41-42.	1.4	1
136	Mesenchymal Stem Cells as Vehicles for Genetic Targeting of Tumors. , 2006, , 157-175.		0
137	Testing the Limits: The Potential of MAPC in Animal Models. , 2006, , 147-156.		0
138	Adoptive Immunotherapy: Guidelines and Clinical Practice. , 2006, , 221-231.		0
139	Developmental Potential of Somatic Stem Cells Following Injection into Murine Blastocysts. , 2006, , 133-146.		0
140	Increasing Impact of Micro RNAs in Stem Cell Biology and Medicine. , 2006, , 43-54.		0
141	Novel Strategies for the Mobilization of Hematopoietic Stem Cells. , 2006, , 55-71.		0
142	A Large Animal Non-Injury Model for Study of Human Stem Cell Plasticity. , 2006, , 119-132.		0
143	The Clonal Activity of Marked Hematopoietic Stem Cells. , 2006, , 107-118.		0
144	Stem Cells and Bypass Grafting for Myocardial and Vascular Regeneration. , 2006, , 197-220.		0

#	ARTICLE	IF	CITATIONS
145	Immune Escape and Suppression by Human Mesenchymal Stem Cells. , 2006, , 233-245.		0
146	Functional Activity of In Vivo Primed Granulocytes: A Comparative Study.. Blood, 2004, 104, 3818-3818.	1.4	0
147	Myeloablative Conditioning in Myelofibrosis using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation with High Doses of CD34+ Cells Results in Hematologic Responses - Follow-Up of Three Patients.. Blood, 2004, 104, 5220-5220.	1.4	0
148	Functional Activity of Granulocytes Primed In Vivo with Glycosylated Granulocyte Colony-Stimulating Factor (G-CSF) Is Superior To Priming with Non-Glycosylated G-CSF.. Blood, 2005, 106, 3865-3865.	1.4	0
149	Upfront Autologous Stem Cell Transplantation (SCT) Ameliorates the Prognostic Disadvantage of an Intermediate/High-Risk FLIPI Score in Patients with Advanced Follicular Lymphoma (FL): Evidence from Two Independent Data Sets.. Blood, 2005, 106, 2070-2070.	1.4	0
150	Genomic and Proteomic Signatures of Human Mesenchymal Stem Cells.. Blood, 2005, 106, 2300-2300.	1.4	0
151	High-Dose Melphalan Chemotherapy with Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: No Increased Mortality Using Induction and Mobilization Chemotherapy.. Blood, 2005, 106, 5505-5505.	1.4	0
152	Generation and Application of a CML-Specific Recombinant Adeno-Associated Virus (rAAV) Vector.. Blood, 2005, 106, 4417-4417.	1.4	0
153	Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.. Blood, 2006, 108, 3018-3018.	1.4	0
154	Synergistic Activity of Nilotinib and Established Chemotherapeutic Agents in Imatinib-Sensitive and -Resistant BCR-ABL-Positive Leukemia Cells.. Blood, 2006, 108, 4778-4778.	1.4	0
155	Characterization of Intercellular Junctional Complexes between Human Hematopoietic and Mesenchymal Stem Cells.. Blood, 2006, 108, 1396-1396.	1.4	0
156	Impact of Whole-Body Magnetic Resonance Imaging on Staging in Patients with Newly Diagnosed Plasma Cell Disease.. Blood, 2006, 108, 5061-5061.	1.4	0
157	Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.. Blood, 2007, 110, 5106-5106.	1.4	0
158	Quality of Life in Patients with B-Cell Lymphoma during Maintenance Therapy with the Anti-CD20 Antibody Rituximab.. Blood, 2007, 110, 4471-4471.	1.4	0
159	Rituximab Maintenance Therapy Prolongs Event Free Survival in Patients with CD20+ B-Cell Non-Hodgkin-Lymphoma.. Blood, 2007, 110, 4472-4472.	1.4	0
160	Human Hematopoietic and Mesenchymal Stem Cells Are Interconnected by Cadherin-Catenin Based Junctions.. Blood, 2007, 110, 1410-1410.	1.4	0
161	Hematopoietic Progenitors with Slow Divisional Kinetics Give Rise to T Cell Precursors in the Thymus of the SCID Mouse Transplantation Model and Represent the Subset with Primitive Function.. Blood, 2007, 110, 2232-2232.	1.4	0
162	Polymorphisms of the Transforming Growth Factor Beta 1 (TGFB1) Gene Define a Subgroup of Patients with Late Onset of Disease and Poor Outcome in Multiple Myeloma.. Blood, 2007, 110, 1491-1491.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Spontaneous CD4 and CD8 Memory T Cell Responses Against MUC1 and Carcinoembryonic Antigen in Bone Marrow of Multiple Myeloma Patients.. Blood, 2007, 110, 3533-3533.	1.4	0
164	In Vivo Mobilization of Leukemic Human Precursor-B-ALL Cells by the CXCR4-Antagonist AMD3100 Is Via Secretion of SDF-1 and Synergistically by Catecholamine Action.. Blood, 2008, 112, 1920-1920.	1.4	0
165	Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.. Blood, 2009, 114, 2722-2722.	1.4	0
166	Poor Mobilization of Hematopoietic Stem Cells – Definitions, Incidence, Risk Factors and Impact On Outcome of Autologous Transplantation.. Blood, 2009, 114, 2153-2153.	1.4	0
167	Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients.. Blood, 2009, 114, 3400-3400.	1.4	0
168	Molecular Determinants and Functional Characteristics of Leukemic Stem Cells and Their Interaction with the Niche.. Blood, 2009, 114, 1427-1427.	1.4	0
169	How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).. Blood, 2009, 114, 2687-2687.	1.4	0
170	Comparative in-Vitro Evaluation of the Myeloid Toxicity of Pentostatin and the Novel PNP-Inhibitor Forodesine.. Blood, 2009, 114, 3766-3766.	1.4	0
171	Pentostatin for First-Line Salvage Therapy of Steroid-Refractory Intestinal Acute Graft-Versus-Host Disease; a Dual Center Retrospective Analysis. Blood, 2010, 116, 1274-1274.	1.4	0
172	Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,. Blood, 2011, 118, 3762-3762.	1.4	0
173	Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial. Blood, 2012, 120, 229-229.	1.4	0
174	Aurora-A Polymorphisms in Multiple Myeloma: Implications On Chromosomal Instability. Blood, 2012, 120, 3982-3982.	1.4	0
175	Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.. Blood, 2012, 120, 3086-3086.	1.4	0
176	Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.. Blood, 2012, 120, 2942-2942.	1.4	0
177	Outbreak of Nosocomial Respiratory Syncytial Virus Infections in a Hematology and Transplant Unit.. Blood, 2012, 120, 3032-3032.	1.4	0
178	The Proliferation Inhibitor CDKN1C (P57KIP2) Is Over Expressed in CD34+ Cells of Patients with MDS and Determines a Worse Prognosis Independently of IPSS Score Factors. Blood, 2012, 120, 3820-3820.	1.4	0
179	Analysis of Prognostic Factors in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma and Skeletal Involvement: A Novel Simple Prognostic Score Identifies a Large Group of Low Risk Patients with an Excellent Prognosis. Blood, 2012, 120, 1590-1590.	1.4	0
180	Parenthood in Long-Term Survivors After CHOEP Treatment for Aggressive Lymphoma Is Not Significantly Impaired in Comparison to the General Population. Results From the Mabthera International Trial (MInT) and the DSHNHL NHLB1 Study. Blood, 2012, 120, 3649-3649.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Single Nucleotide Polymorphisms Within The Thrombomodulin Gene (THBD) Predict Risk Of Non-Relapse Mortality In Patients With Graft-Versus-Host Disease. Blood, 2013, 122, 4589-4589.	1.4	0
182	Pre-Transplant Weight Loss and Total Serum Protein Predict Relapse Of Acute Myeloid Leukaemia After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 3314-3314.	1.4	0
183	Understanding The Marrow Niche: Advanced 3D Model System Allows Functional Analysis Of The Interaction With Human Hematopoietic Progenitor Cells. Blood, 2013, 122, 2462-2462.	1.4	0
184	Proteome Analyses and Single-Cell RNA Sequencing Reveal Age-Dependent Re-Wiring of Central Carbon Metabolism in Myeloid-Biased Subsets of Human Hematopoietic Stem Cells. Blood, 2018, 132, 873-873.	1.4	0
185	Prognostic Impact of Gastrointestinal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 5400-5400.	1.4	0